Mazdutide

Third-Party Tested

Independent lab verified

Batch-Specific CoA

Publicly accessible

YPB.269

Reference number

100mg

Lyophilized vial

Origin

Mazdutide (LY3305677/IBI362) was developed through a collaboration between Eli Lilly and Innovent Biologics. It is an oxyntomodulin analog that activates both the GLP-1 receptor and the glucagon receptor, combining the satiety effects of GLP-1 agonism with the energy expenditure effects of glucagon agonism.

Research Lineage

Ji et al. published Phase II clinical trial results from the GLORY-1 and GLORY-2 studies conducted primarily in China. The dual-agonist approach is part of a broader trend in metabolic drug research toward multi-target compounds, following the success of tirzepatide (GLP-1/GIP dual agonist). Innovent is advancing Mazdutide through Phase III trials.

Mechanism of Action

Mazdutide activates both the GLP-1 receptor (satiety, insulin secretion, gastric motility) and the glucagon receptor (hepatic glycogenolysis, energy expenditure, lipid oxidation). The dual mechanism is proposed to produce greater effects on body weight and hepatic fat than GLP-1 agonism alone. The glucagon component may counteract GLP-1-mediated inhibition of energy expenditure.

Structural Notes

Acylated peptide analog of oxyntomodulin. Fatty acid modification for extended half-life. Engineered for a specific GLP-1R/GCGR activity ratio.